中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Scientific Advisory Board
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
News
Press Releases
In The News
Media Room
Jan 17,2023
17
January 2023
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Jul 22,2022
22
July 2022
AIER and AffaMed Therapeutics Reach Strategic Cooperation in Boao LeCheng
May 31,2022
31
May 2022
AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease
May 25,2022
25
May 2022
AffaMed Therapeutics Announces Strategic Partnership with Primal Chemical to Market IOLs and DEXTENZA in Hong Kong and Macau
May 10,2022
10
May 2022
AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
<<
<
1
2
3
4
5
6
7
>
>>
上一页
下一页
